Resources on a range of topics relevant to Living with Idiopathic Hypersomnia and Narcolepsy. Check back here regularly as we add to our library. https://t.co/D3mbT2yzVv #LivingwithIH #IdiopathicHypersomnia #narcolepsy #LivingwithNarcolepsy

The next Living with #Narcolepsy Catch Up is THIS Wednesday 1st October, 6.30pm AEST. Register here: https://t.co/W43Bq1lUk9

🗣️ Your voice matters. 👉 Survey: https://t.co/D3j67z8mkg This quick, anonymous survey will help guide how HA speaks up for our community in policy & advocacy. 🔒 No names or emails are collected - Please feel free to be completely open. #narcolepsy #IdiopathicHypersomnia

Meet people you can relate to - the next Living with #Narcolepsy Catch Up is Wed 1st Oct, 6.30pm AEST. More info https://t.co/0HxZ7KiRHh Read real stories & learn about narcolepsy: https://t.co/j8jCSRhi8K #LivingwithNarcolepsy #Narcolepsy #WorldNarcolepsyDay

✨Today is WORLD NARCOLEPSY DAY!✨ Read real stories, learn about narcolepsy, and find support: https://t.co/j8jCSRhi8K #WorldNarcolepsyDay #NarcolepsyAwareness #Narcolepsy #LivingWithNarcolepsy

“Narcolepsy is a joke in pop culture, affecting those who have it” Dr. Aaron Schokman, a lived experience (narcolepsy type 1) Research Fellow Uni of Sydney. https://t.co/YCMGR6Pvhr #WorldNarcolepsyDay

Monday, 22nd September is WORLD NARCOLEPSY DAY! Read real stories, learn about narcolepsy, and find support: https://t.co/j8jCSRhi8K #WorldNarcolepsyDay

We’re hosting an in person community catch up! 📍 River Torrens, Adelaide 🗓 Saturday 11 October ⏰ 10am For people living with #Narcolepsy or #IdiopathicHypersomnia 👉 If you’d like to join us, keep an eye on this post - we’ll share the exact meeting spot closer to the day.

Packed house! One of the true highlights of #WorldSleep2025. Thank you to all the researchers involved & @Alkermes, and @TakedaPharma for their continued commitment to advancing outcomes for people living with #Narcolepsy & #idiopathichypersomnia

Im excited to be in Singapore this week for #WorldSleep2025. It’s inspiring to see lived experience and research come together on a global stage, and to ensure that people with idiopathic hypersomnia and narcolepsy are part of the conversation.

🌏✨ World Sleep 2025 – Singapore ✨🌏 This week, Hypersomnolence Australia’s Michelle Chadwick is in Singapore for the World Sleep Congress, proudly representing people living with #idiopathichypersomnia (IH) and #narcolepsy. #WorldSleep2025

Living with IH? Join the registry: https://t.co/dzm2CCVe6E We’re in the process of expanding our registry to include ALL Central Disorders of Hypersomnolence (narcolepsy, KLS), making this registry even more powerful. 🔗 Read more about the findings: https://t.co/U8PLno2NUC

Support for people diagnosed with #narcolepsy and living in Australia REGISTER: https://t.co/W43Bq1lUk9 More info: https://t.co/0HxZ7KiRHh

HOW TO ACCESS XYREM (Sodium Oxybate) in Australia - and why it isnt TGA registered or PBS listed. This article also explains how you may (if you qualify) apply through public hospital programs to have the cost subsidised https://t.co/dJnFstuejE #Narcolepsy #IdiopathicHypersomnia

#Narcolepsy #IdiopathicHypersomnia Research volunteers required. Register your interest: https://t.co/LW99tnEcmL

If you live in Australia & have been diagnosed with #IdiopathicHypersomnia & would like to attend, register here: https://t.co/ikBZzY064c

Other study sites will begin recruiting soon. If you're in SA, you can contact Alison Teare at alison.teare@flinders.edu.au. Contact details for the Victorian site will be shared as soon as they are available. For more information: https://t.co/rPFqLjpyXI #orexin #Alkermes

VIBRANCE-3: Orexin Agonist Study for Idiopathic Hypersomnia - STUDY VOLUNTEERS NEEDED **ONLY THOSE LIVING IN NSW & QLD** Email: hypersomnolence@woolcock.org.au if you are interested in this study. See comments for details of other sites… #Alkermes #idiopathichypersomnia

If you live in Australia, have been diagnosed with #narcolepsy and would like to attend (and have not registered before) you can do so here: https://t.co/W43Bq1lmuB

Alkermes announced positive topline results from its Vibrance 1 Phase 2 trial of alixorexton, a once daily oral orexin 2 receptor agonist aimed at treating narcolepsy type 1. Press Release: https://t.co/hlVwrRVHX0 #narcolepsy #sleepmedicine #orexinagonist #Alkermes #Vibrance1

#Narcolepsy #IdiopathicHypersomnia Research volunteers required. Register your interest: https://t.co/LW99tnEcmL